Arkolith/Insider Trading/SNDX/Form 4

Podlesak Dennis

DirectorSyndax Pharmaceuticals Inc (SNDX) · full profile →Form 4 · filed Aug 18, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$875K
Net Open-Market Flow
-$875K
Transactions
10
6 non-derivative · 4 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Aug 18, 2025Option exercise(M)19K$7.20$138K211K
Aug 18, 2025Sell(S)19K$15.84$304K192K
Aug 15, 2025Sell(S)19K$15.54$298K192K
Aug 15, 2025Option exercise(M)19K$7.20$138K211K
Aug 14, 2025Option exercise(M)19K$7.20$138K211K
Aug 14, 2025Sell(S)19K$14.19$272K192K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Aug 18, 2025Option exercise(M)19K—$00
Aug 15, 2025Option exercise(M)14K—$00
Aug 15, 2025Option exercise(M)5K—$00
Aug 14, 2025Option exercise(M)19K—$00

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-25-109815) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML